{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T19:16:54Z","timestamp":1787599014225,"version":"build-2736575974"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"20","license":[{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000771","name":"Prostate Cancer UK","doi-asserted-by":"publisher","award":["RIA19-ST2-004"],"award-info":[{"award-number":["RIA19-ST2-004"]}],"id":[{"id":"10.13039\/501100000771","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"UKRI | Medical Research Council","doi-asserted-by":"publisher","award":["MR\/V009354\/1"],"award-info":[{"award-number":["MR\/V009354\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"UKRI | Medical Research Council","doi-asserted-by":"publisher","award":["MR\/R015732\/1"],"award-info":[{"award-number":["MR\/R015732\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EMBO J"],"published-print":{"date-parts":[[2025,10,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>CDK7 has emerged as a cancer target because of its pivotal roles in cell cycle progression and transcription. Several CDK7 inhibitors (CDK7i) are now in clinical evaluation. Identifying patients most likely to respond to treatment and early detection of tumour evolution towards resistance are necessary for optimal implementation of cancer therapies. Continuous culturing of prostate cancer cells with Samuraciclib, a non-covalent ATP-competitive CDK7i, led to outgrowth of resistant cells. These were characterised by the acquisition of a single base change in the CDK7 gene, Asp97 to Asn (D97N). Mutant cells were resistant to other non-covalent CDK7i but remained sensitive to covalent CDK7i. Cryo-EM structure and kinase ligand affinity determinations revealed reduced affinity of the CDK7-D97N mutant for non-covalent CDK7i. Remarkably, Asp97 is absolutely conserved in human CDKs, inferring its importance for the activities of all CDKs. Consistent with this, mutation of the homologous residue in CDK12 (D819N) or CDK4 (D99N) promoted resistance to drugs that inhibit these CDKs. Our findings reveal a general mechanism for acquired resistance with obvious implications for patients treated with CDK inhibitors.<\/jats:p>","DOI":"10.1038\/s44318-025-00554-6","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T15:46:18Z","timestamp":1757346378000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Resistance to CDK7 inhibitors directed by acquired mutation of a conserved residue in cancer cells"],"prefix":"10.1038","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9967-8054","authenticated-orcid":false,"given":"Chun-Fui","family":"Lai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria I","family":"Cushing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8430-9969","authenticated-orcid":false,"given":"Ellen","family":"Olden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7533-0552","authenticated-orcid":false,"given":"Charlotte L","family":"Bevan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4811-1100","authenticated-orcid":false,"given":"R Charles","family":"Coombes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9379-7159","authenticated-orcid":false,"given":"Basil J","family":"Greber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6973-334X","authenticated-orcid":false,"given":"Laki","family":"Buluwela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1320-0816","authenticated-orcid":false,"given":"Simak","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,8]]},"reference":[{"key":"554_CR1","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1107\/S2059798318006551","volume":"74","author":"PV Afonine","year":"2018","unstructured":"Afonine PV, Poon BK, Read RJ, Sobolev OV, Terwilliger TC, Urzhumtsev A, Adams PD (2018) Real-space refinement in PHENIX for cryo-EM and crystallography. Acta Crystallogr D Struct Biol 74:531\u2013544","journal-title":"Acta Crystallogr D Struct Biol"},{"key":"554_CR2","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1146\/annurev-med-052209-100305","volume":"62","author":"S Ali","year":"2011","unstructured":"Ali S, Buluwela L, Coombes RC (2011) Antiestrogens and their therapeutic applications in breast cancer and other diseases. Annu Rev Med 62:217\u2013232","journal-title":"Annu Rev Med"},{"key":"554_CR3","doi-asserted-by":"crossref","first-page":"6208","DOI":"10.1158\/0008-5472.CAN-09-0301","volume":"69","author":"S Ali","year":"2009","unstructured":"Ali S, Heathcote DA, Kroll SH, Jogalekar AS, Scheiper B, Patel H, Brackow J, Siwicka A, Fuchter MJ, Periyasamy M et al (2009) The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity. Cancer Res 69:6208\u20136215","journal-title":"Cancer Res"},{"key":"554_CR4","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1200\/PO.19.00399","volume":"4","author":"ES Antonarakis","year":"2020","unstructured":"Antonarakis ES, Isaacsson Velho P, Fu W, Wang H, Agarwal N, Sacristan Santos V, Maughan BL, Pili R, Adra N, Sternberg CN et al (2020) CDK12-altered prostate cancer: clinical features and therapeutic outcomes to standard systemic therapies, poly (ADP-ribose) polymerase inhibitors, and PD-1 inhibitors. JCO Precis Oncol 4:370\u2013381","journal-title":"JCO Precis Oncol"},{"key":"554_CR5","doi-asserted-by":"crossref","first-page":"2628.e21","DOI":"10.1016\/j.cell.2023.05.013","volume":"186","author":"M Arora","year":"2023","unstructured":"Arora M, Moser J, Hoffman TE, Watts LP, Min M, Musteanu M, Rong Y, Ill CR, Nangia V, Schneider J et al (2023) Rapid adaptation to CDK2 inhibition exposes intrinsic cell-cycle plasticity. Cell 186:2628.e21\u20132643.e21","journal-title":"Cell"},{"key":"554_CR78","doi-asserted-by":"publisher","unstructured":"Asarnow D, Palovcak E, Cheng Y (2019) UCSF pyem v0.5. Zenodo. https:\/\/doi.org\/10.5281\/zenodo.3576630","DOI":"10.5281\/zenodo.3576630"},{"key":"554_CR6","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1158\/0008-5472.CAN-13-2541","volume":"74","author":"I Bajrami","year":"2014","unstructured":"Bajrami I, Frankum JR, Konde A, Miller RE, Rehman FL, Brough R, Campbell J, Sims D, Rafiq R, Hooper S et al (2014) Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1\/2 inhibitor sensitivity. Cancer Res 74:287\u2013297","journal-title":"Cancer Res"},{"key":"554_CR7","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/nature08822","volume":"463","author":"R Beroukhim","year":"2010","unstructured":"Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M et al (2010) The landscape of somatic copy-number alteration across human cancers. Nature 463:899\u2013905","journal-title":"Nature"},{"key":"554_CR8","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.celrep.2016.09.061","volume":"17","author":"L Brenan","year":"2016","unstructured":"Brenan L, Andreev A, Cohen O, Pantel S, Kamburov A, Cacchiarelli D, Persky NS, Zhu C, Bagul M, Goetz EM et al (2016) Phenotypic characterization of a comprehensive set of MAPK1\/ERK2 missense mutants. Cell Rep 17:1171\u20131183","journal-title":"Cell Rep"},{"key":"554_CR9","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1158\/1535-7163.MCT-16-0300","volume":"15","author":"P Chen","year":"2016","unstructured":"Chen P, Lee NV, Hu W, Xu M, Ferre RA, Lam H, Bergqvist S, Solowiej J, Diehl W, He YA et al (2016) Spectrum and degree of CDK drug interactions predicts clinical performance. Mol Cancer Ther 15:2273\u20132281","journal-title":"Mol Cancer Ther"},{"key":"554_CR10","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.cell.2014.10.024","volume":"159","author":"E Chipumuro","year":"2014","unstructured":"Chipumuro E, Marco E, Christensen CL, Kwiatkowski N, Zhang T, Hatheway CM, Abraham BJ, Sharma B, Yeung C, Altabef A et al (2014) CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer. Cell 159:1126\u20131139","journal-title":"Cell"},{"key":"554_CR11","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1158\/2159-8290.CD-19-0528","volume":"10","author":"J Chou","year":"2020","unstructured":"Chou J, Quigley DA, Robinson TM, Feng FY, Ashworth A (2020) Transcription-associated cyclin-dependent kinases as targets and biomarkers for cancer therapy. Cancer Discov 10:351\u2013370","journal-title":"Cancer Discov"},{"key":"554_CR12","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.ccell.2014.10.019","volume":"26","author":"CL Christensen","year":"2014","unstructured":"Christensen CL, Kwiatkowski N, Abraham BJ, Carretero J, Al-Shahrour F, Zhang T, Chipumuro E, Herter-Sprie GS, Akbay EA, Altabef A et al (2014) Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor. Cancer Cell 26:909\u2013922","journal-title":"Cancer Cell"},{"key":"554_CR13","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1038\/s41416-023-02252-8","volume":"128","author":"TA Constantin","year":"2023","unstructured":"Constantin TA, Varela-Carver A, Greenland KK, de Almeida GS, Olden E, Penfold L, Ang S, Ormrod A, Leach DA, Lai CF et al (2023) The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer. Br J Cancer 128:2326\u20132337","journal-title":"Br J Cancer"},{"key":"554_CR14","volume":"14","author":"RC Coombes","year":"2023","unstructured":"Coombes RC, Howell S, Lord SR, Kenny L, Mansi J, Mitri Z, Palmieri C, Chap LI, Richards P, Gradishar W et al (2023) Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib. Nat Commun 14:4444","journal-title":"Nat Commun"},{"key":"554_CR15","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-46375-9","volume":"15","author":"VI Cushing","year":"2024","unstructured":"Cushing VI, Koh AF, Feng J, Jurgaityte K, Bondke A, Kroll SHB, Barbazanges M, Scheiper B, Bahl AK, Barrett AGM et al (2024) High-resolution cryo-EM of the human CDK-activating kinase for structure-based drug design. Nat Commun 15:2265","journal-title":"Nat Commun"},{"key":"554_CR16","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1158\/2159-8290.CD-23-0954","volume":"14","author":"C Dietrich","year":"2024","unstructured":"Dietrich C, Trub A, Ahn A, Taylor M, Ambani K, Chan KT, Lu KH, Mahendra CA, Blyth C, Coulson R et al (2024) INX-315, a selective CDK2 inhibitor, induces cell cycle arrest and senescence in solid tumors. Cancer Discov 14:446\u2013467","journal-title":"Cancer Discov"},{"key":"554_CR17","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1107\/S0907444910007493","volume":"66","author":"P Emsley","year":"2010","unstructured":"Emsley P, Lohkamp B, Scott WG, Cowtan K (2010) Features and development of Coot. Acta Crystallogr D Biol Crystallogr 66:486\u2013501","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"554_CR18","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1517\/17425255.2.6.923","volume":"2","author":"JC Erve","year":"2006","unstructured":"Erve JC (2006) Chemical toxicology: reactive intermediates and their role in pharmacology and toxicology. Expert Opin Drug Metab Toxicol 2:923\u2013946","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"554_CR19","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1080\/21541264.2018.1556915","volume":"10","author":"CB Fant","year":"2019","unstructured":"Fant CB, Taatjes DJ (2019) Regulatory functions of the mediator kinases CDK8 and CDK19. Transcription 10:76\u201390","journal-title":"Transcription"},{"key":"554_CR20","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/21541264.2018.1553483","volume":"10","author":"RP Fisher","year":"2019","unstructured":"Fisher RP (2019) Cdk7: a kinase at the core of transcription and in the crosshairs of cancer drug discovery. Transcription 10:47\u201356","journal-title":"Transcription"},{"key":"554_CR21","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/pro.3235","volume":"27","author":"TD Goddard","year":"2018","unstructured":"Goddard TD, Huang CC, Meng EC, Pettersen EF, Couch GS, Morris JH, Ferrin TE (2018) UCSF ChimeraX: meeting modern challenges in visualization and analysis. Protein Sci 27:14\u201325","journal-title":"Protein Sci"},{"key":"554_CR22","doi-asserted-by":"crossref","first-page":"22849","DOI":"10.1073\/pnas.2009627117","volume":"117","author":"BJ Greber","year":"2020","unstructured":"Greber BJ, Perez-Bertoldi JM, Lim K, Iavarone AT, Toso DB, Nogales E (2020) The cryoelectron microscopy structure of the human CDK-activating kinase. Proc Natl Acad Sci USA 117:22849\u201322857","journal-title":"Proc Natl Acad Sci USA"},{"key":"554_CR23","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-34179-8","volume":"13","author":"T Houles","year":"2022","unstructured":"Houles T, Lavoie G, Nourreddine S, Cheung W, Vaillancourt-Jean E, Guerin CM, Bouttier M, Grondin B, Lin S, Saba-El-Leil MK et al (2022) CDK12 is hyperactivated and a synthetic-lethal target in BRAF-mutated melanoma. Nat Commun 13:6457","journal-title":"Nat Commun"},{"key":"554_CR24","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1101\/gad.200303.112","volume":"26","author":"JP Hsin","year":"2012","unstructured":"Hsin JP, Manley JL (2012) The RNA polymerase II CTD coordinates transcription and RNA processing. Genes Dev 26:2119\u20132137","journal-title":"Genes Dev"},{"key":"554_CR25","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1128\/AAC.04534-14","volume":"59","author":"C Hutterer","year":"2015","unstructured":"Hutterer C, Eickhoff J, Milbradt J, Korn K, Zeittrager I, Bahsi H, Wagner S, Zischinsky G, Wolf A, Degenhart C et al (2015) A novel CDK7 inhibitor of the Pyrazolotriazine class exerts broad-spectrum antiviral activity at nanomolar concentrations. Antimicrob Agents Chemother 59:2062\u20132071","journal-title":"Antimicrob Agents Chemother"},{"key":"554_CR26","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature12634","volume":"502","author":"C Kandoth","year":"2013","unstructured":"Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA et al (2013) Mutational landscape and significance across 12 major cancer types. Nature 502:333\u2013339","journal-title":"Nature"},{"key":"554_CR27","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/s41592-024-02304-8","volume":"21","author":"D Kimanius","year":"2024","unstructured":"Kimanius D, Jamali K, Wilkinson ME, Lovestam S, Velazhahan V, Nakane T, Scheres SHW (2024) Data-driven regularization lowers the size barrier of cryo-EM structure determination. Nat Methods 21:1216\u20131221","journal-title":"Nat Methods"},{"key":"554_CR28","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/nature13393","volume":"511","author":"N Kwiatkowski","year":"2014","unstructured":"Kwiatkowski N, Zhang T, Rahl PB, Abraham BJ, Reddy J, Ficarro SB, Dastur A, Amzallag A, Ramaswamy S, Tesar B et al (2014) Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature 511:616\u2013620","journal-title":"Nature"},{"key":"554_CR29","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/nsmb.2399","volume":"19","author":"S Larochelle","year":"2012","unstructured":"Larochelle S, Amat R, Glover-Cutter K, Sanso M, Zhang C, Allen JJ, Shokat KM, Bentley DL, Fisher RP (2012) Cyclin-dependent kinase control of the initiation-to-elongation switch of RNA polymerase II. Nat Struct Mol Biol 19:1108\u20131115","journal-title":"Nat Struct Mol Biol"},{"key":"554_CR30","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature12912","volume":"505","author":"MS Lawrence","year":"2014","unstructured":"Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, Meyerson M, Gabriel SB, Lander ES, Getz G (2014) Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505:495\u2013501","journal-title":"Nature"},{"issue":"6","key":"554_CR31","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.celrep.2013.08.022","volume":"4","author":"S Li","year":"2013","unstructured":"Li S, Shen D, Shao J, Crowder R, Liu W, Prat A, He X, Liu S, Hoog J, Lu C et al (2013) Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep 4(6):1116\u20131130","journal-title":"Cell Rep"},{"key":"554_CR32","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cell.2012.08.026","volume":"151","author":"CY Lin","year":"2012","unstructured":"Lin CY, Loven J, Rahl PB, Paranal RM, Burge CB, Bradner JE, Lee TI, Young RA (2012) Transcriptional amplification in tumor cells with elevated c-Myc. Cell 151:56\u201367","journal-title":"Cell"},{"key":"554_CR33","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1158\/0008-5472.CAN-20-2245","volume":"81","author":"H Liu","year":"2021","unstructured":"Liu H, Liu K, Dong Z (2021) Targeting CDK12 for cancer therapy: function, mechanism, and drug discovery. Cancer Res 81:18\u201326","journal-title":"Cancer Res"},{"key":"554_CR34","doi-asserted-by":"crossref","DOI":"10.1186\/gb4184","volume":"15","author":"M Malumbres","year":"2014","unstructured":"Malumbres M (2014) Cyclin-dependent kinases. Genome Biol 15:122","journal-title":"Genome Biol"},{"key":"554_CR35","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1021\/acs.jmedchem.1c01171","volume":"65","author":"JJ Marineau","year":"2022","unstructured":"Marineau JJ, Hamman KB, Hu S, Alnemy S, Mihalich J, Kabro A, Whitmore KM, Winter DK, Roy S, Ciblat S et al (2022) Discovery of SY-5609: a selective, noncovalent inhibitor of CDK7. J Med Chem 65:1458\u20131480","journal-title":"J Med Chem"},{"key":"554_CR36","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","volume":"397","author":"AR Mato","year":"2021","unstructured":"Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM, Woyach JA, Fakhri B, Eyre TA, Lamanna N, Patel MR et al (2021) Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study. Lancet 397:892\u2013901","journal-title":"Lancet"},{"key":"554_CR37","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41580-021-00404-3","volume":"23","author":"HK Matthews","year":"2022","unstructured":"Matthews HK, Bertoli C, de Bruin RAM (2022) Cell cycle control in cancer. Nat Rev Mol Cell Biol 23:74\u201388","journal-title":"Nat Rev Mol Cell Biol"},{"key":"554_CR38","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.molcel.2008.10.022","volume":"32","author":"KA Merrick","year":"2008","unstructured":"Merrick KA, Larochelle S, Zhang C, Allen JJ, Shokat KM, Fisher RP (2008) Distinct activation pathways confer cyclin-binding specificity on Cdk1 and Cdk2 in human cells. Mol Cell 32:662\u2013672","journal-title":"Mol Cell"},{"key":"554_CR39","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1146\/annurev.cellbio.13.1.261","volume":"13","author":"DO Morgan","year":"1997","unstructured":"Morgan DO (1997) Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu Rev Cell Dev Biol 13:261\u2013291","journal-title":"Annu Rev Cell Dev Biol"},{"key":"554_CR40","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41571-023-00840-4","volume":"21","author":"L Morrison","year":"2024","unstructured":"Morrison L, Loibl S, Turner NC (2024) The CDK4\/6 inhibitor revolution - a game-changing era for breast cancer treatment. Nat Rev Clin Oncol 21:89\u2013105","journal-title":"Nat Rev Clin Oncol"},{"key":"554_CR41","first-page":"1040.e3","volume":"32","author":"M Mukherjee","year":"2024","unstructured":"Mukherjee M, Day PJ, Laverty D, Bueren-Calabuig JA, Woodhead AJ, Griffiths-Jones C, Hiscock S, East C, Boyd S, O\u2019Reilly M (2024) Protein engineering enables a soakable crystal form of human CDK7 primed for high-throughput crystallography and structure-based drug design. Structure 32:1040.e3\u20131048.e3","journal-title":"Structure"},{"key":"554_CR42","doi-asserted-by":"crossref","first-page":"792.e10","DOI":"10.1016\/j.chembiol.2019.02.012","volume":"26","author":"CM Olson","year":"2019","unstructured":"Olson CM, Liang Y, Leggett A, Park WD, Li L, Mills CE, Elsarrag SZ, Ficarro SB, Zhang T, Duster R et al (2019) Development of a selective CDK7 covalent inhibitor reveals predominant cell-cycle phenotype. Cell Chem Biol 26:792.e10\u2013803.e10","journal-title":"Cell Chem Biol"},{"key":"554_CR43","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/s41589-020-0563-4","volume":"16","author":"PK Parua","year":"2020","unstructured":"Parua PK, Fisher RP (2020) Dissecting the Pol II transcription cycle and derailing cancer with CDK inhibitors. Nat Chem Biol 16:716\u2013724","journal-title":"Nat Chem Biol"},{"key":"554_CR44","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1158\/1535-7163.MCT-16-0847","volume":"17","author":"H Patel","year":"2018","unstructured":"Patel H, Periyasamy M, Sava GP, Bondke A, Slafer BW, Kroll SHB, Barbazanges M, Starkey R, Ottaviani S, Harrod A et al (2018) ICEC0942, an orally bioavailable selective inhibitor of CDK7 for cancer treatment. Mol Cancer Ther 17:1156\u20131166","journal-title":"Mol Cancer Ther"},{"key":"554_CR45","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41594-019-0358-z","volume":"27","author":"NS Persky","year":"2020","unstructured":"Persky NS, Hernandez D, Do Carmo M, Brenan L, Cohen O, Kitajima S, Nayar U, Walker A, Pantel S, Lee Y et al (2020) Defining the landscape of ATP-competitive inhibitor resistance residues in protein kinases. Nat Struct Mol Biol 27:92\u2013104","journal-title":"Nat Struct Mol Biol"},{"key":"554_CR46","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/pro.3943","volume":"30","author":"EF Pettersen","year":"2021","unstructured":"Pettersen EF, Goddard TD, Huang CC, Meng EC, Couch GS, Croll TI, Morris JH, Ferrin TE (2021) UCSF ChimeraX: structure visualization for researchers, educators, and developers. Protein Sci 30:70\u201382","journal-title":"Protein Sci"},{"key":"554_CR47","doi-asserted-by":"crossref","DOI":"10.1093\/narcan\/zcaa003","volume":"2","author":"K Pilarova","year":"2020","unstructured":"Pilarova K, Herudek J, Blazek D (2020) CDK12: cellular functions and therapeutic potential of versatile player in cancer. NAR Cancer 2:zcaa003","journal-title":"NAR Cancer"},{"key":"554_CR48","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/s41592-020-0731-1","volume":"17","author":"G Pintilie","year":"2020","unstructured":"Pintilie G, Zhang K, Su Z, Li S, Schmid MF, Chiu W (2020) Measurement of atom resolvability in cryo-EM maps with Q-scores. Nat Methods 17:328\u2013334","journal-title":"Nat Methods"},{"key":"554_CR49","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nmeth.4169","volume":"14","author":"A Punjani","year":"2017","unstructured":"Punjani A, Rubinstein JL, Fleet DJ, Brubaker MA (2017) cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat Methods 14:290\u2013296","journal-title":"Nat Methods"},{"key":"554_CR50","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41572-020-00243-0","volume":"7","author":"RJ Rebello","year":"2021","unstructured":"Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, Gillessen S, Van der Kwast T, Bristow RG (2021) Prostate cancer. Nat Rev Dis Primers 7:9","journal-title":"Nat Rev Dis Primers"},{"key":"554_CR51","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1101\/gad.341545.120","volume":"34","author":"JK Rimel","year":"2020","unstructured":"Rimel JK, Poss ZC, Erickson B, Maas ZL, Ebmeier CC, Johnson JL, Decker TM, Yaron TM, Bradley MJ, Hamman KB et al (2020) Selective inhibition of CDK7 reveals high-confidence targets and new models for TFIIH function in transcription. Genes Dev 34:1452\u20131473","journal-title":"Genes Dev"},{"issue":"12","key":"554_CR52","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/ng.2823","volume":"45","author":"DR Robinson","year":"2013","unstructured":"Robinson DR, Wu YM, Vats P, Su F, Lonigro RJ, Cao X, Kalyana-Sundaram S, Wang R, Ning Y, Hodges L et al (2013) Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet 45(12):1446\u20131451","journal-title":"Nat Genet"},{"key":"554_CR53","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.jmb.2003.07.013","volume":"333","author":"PB Rosenthal","year":"2003","unstructured":"Rosenthal PB, Henderson R (2003) Optimal determination of particle orientation, absolute hand, and contrast loss in single-particle electron cryomicroscopy. J Mol Biol 333:721\u2013745","journal-title":"J Mol Biol"},{"key":"554_CR54","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s10555-020-09885-8","volume":"39","author":"GP Sava","year":"2020","unstructured":"Sava GP, Fan H, Coombes RC, Buluwela L, Ali S (2020) CDK7 inhibitors as anticancer drugs. Cancer Metastasis Rev 39:805\u2013823","journal-title":"Cancer Metastasis Rev"},{"key":"554_CR55","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.4161\/cc.26355","volume":"12","author":"MM Schachter","year":"2013","unstructured":"Schachter MM, Fisher RP (2013) The CDK-activating kinase Cdk7: taking yes for an answer. Cell Cycle 12:3239\u20133240","journal-title":"Cell Cycle"},{"key":"554_CR56","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.molcel.2013.04.003","volume":"50","author":"MM Schachter","year":"2013","unstructured":"Schachter MM, Merrick KA, Larochelle S, Hirschi A, Zhang C, Shokat KM, Rubin SM, Fisher RP (2013) A Cdk7-Cdk4 T-loop phosphorylation cascade promotes G1 progression. Mol Cell 50:250\u2013260","journal-title":"Mol Cell"},{"key":"554_CR57","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.jsb.2012.09.006","volume":"180","author":"SH Scheres","year":"2012","unstructured":"Scheres SH (2012) RELION: implementation of a Bayesian approach to cryo-EM structure determination. J Struct Biol 180:519\u2013530","journal-title":"J Struct Biol"},{"key":"554_CR58","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.105501","volume":"300","author":"M Schmitz","year":"2024","unstructured":"Schmitz M, Kaltheuner IH, Anand K, Duster R, Moecking J, Monastyrskyi A, Duckett DR, Roush WR, Geyer M (2024) The reversible inhibitor SR-4835 binds Cdk12\/cyclin K in a noncanonical G-loop conformation. J Biol Chem 300:105501","journal-title":"J Biol Chem"},{"key":"554_CR59","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","volume":"9","author":"CA Schneider","year":"2012","unstructured":"Schneider CA, Rasband WS, Eliceiri KW (2012) NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9:671\u2013675","journal-title":"Nat Methods"},{"key":"554_CR60","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrd3410","volume":"10","author":"J Singh","year":"2011","unstructured":"Singh J, Petter RC, Baillie TA, Whitty A (2011) The resurgence of covalent drugs. Nat Rev Drug Discov 10:307\u2013317","journal-title":"Nat Rev Drug Discov"},{"key":"554_CR61","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/jnci\/82.13.1107","volume":"82","author":"P Skehan","year":"1990","unstructured":"Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107\u20131112","journal-title":"J Natl Cancer Inst"},{"key":"554_CR62","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41586-020-2374-x","volume":"585","author":"M Slabicki","year":"2020","unstructured":"Slabicki M, Kozicka Z, Petzold G, Li YD, Manojkumar M, Bunker RD, Donovan KA, Sievers QL, Koeppel J, Suchyta D et al (2020) The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K. Nature 585:293\u2013297","journal-title":"Nature"},{"key":"554_CR63","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s11626-999-0115-4","volume":"35","author":"RM Sramkoski","year":"1999","unstructured":"Sramkoski RM, Pretlow 2nd TG, Giaconia JM, Pretlow TP, Schwartz S, Sy MS, Marengo SR, Rhim JS, Zhang D, Jacobberger JW (1999) A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim 35:403\u2013409","journal-title":"In Vitro Cell Dev Biol Anim"},{"key":"554_CR64","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.ccell.2021.03.010","volume":"39","author":"JM Suski","year":"2021","unstructured":"Suski JM, Braun M, Strmiska V, Sicinski P (2021) Targeting cell-cycle machinery in cancer. Cancer cell 39:759\u2013778","journal-title":"Cancer cell"},{"key":"554_CR65","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1021\/acs.jmedchem.6b01670","volume":"60","author":"S Tadesse","year":"2017","unstructured":"Tadesse S, Yu M, Mekonnen LB, Lam F, Islam S, Tomusange K, Rahaman MH, Noll B, Basnet SK, Teo T et al (2017) Highly potent, selective, and orally bioavailable 4-thiazol-N-(pyridin-2-yl)pyrimidin-2-amine cyclin-dependent kinases 4 and 6 inhibitors as anticancer drug candidates: design, synthesis, and evaluation. J Med Chem 60:1892\u20131915","journal-title":"J Med Chem"},{"issue":"12","key":"554_CR66","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/ng.2822","volume":"45","author":"W Toy","year":"2013","unstructured":"Toy W, Shen Y, Won H, Green B, Sakr RA, Will M, Li Z, Gala K, Fanning S, King TA et al (2013) ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet 45(12):1439\u20131445","journal-title":"Nat Genet"},{"key":"554_CR67","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.cell.2015.08.063","volume":"163","author":"Y Wang","year":"2015","unstructured":"Wang Y, Zhang T, Kwiatkowski N, Abraham BJ, Lee TI, Xie S, Yuzugullu H, Von T, Li H, Lin Z et al (2015) CDK7-dependent transcriptional addiction in triple-negative breast cancer. Cell 163:174\u2013186","journal-title":"Cell"},{"key":"554_CR68","first-page":"1388","volume":"10","author":"KE Weis","year":"1996","unstructured":"Weis KE, Ekena K, Thomas JA, Lazennec G, Katzenellenbogen BS (1996) Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein. Mol Endocrinol 10:1388\u20131398","journal-title":"Mol Endocrinol"},{"key":"554_CR69","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-16559-0","volume":"11","author":"CI Wells","year":"2020","unstructured":"Wells CI, Vasta JD, Corona CR, Wilkinson J, Zimprich CA, Ingold MR, Pickett JE, Drewry DH, Pugh KM, Schwinn MK et al (2020) Quantifying CDK inhibitor selectivity in live cells. Nat Commun 11:2743","journal-title":"Nat Commun"},{"key":"554_CR70","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1093\/emboj\/16.6.1427","volume":"16","author":"R White","year":"1997","unstructured":"White R, Sjoberg M, Kalkhoven E, Parker MG (1997) Ligand-independent activation of the oestrogen receptor by mutation of a conserved tyrosine. EMBO J 16:1427\u20131435","journal-title":"EMBO J"},{"key":"554_CR71","doi-asserted-by":"crossref","first-page":"180112","DOI":"10.1098\/rsob.180112","volume":"8","author":"DJ Wood","year":"2018","unstructured":"Wood DJ, Endicott JA (2018) Structural insights into the functional diversity of the CDK-cyclin family. Open Biol 8:180112","journal-title":"Open Biol"},{"key":"554_CR72","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","volume":"35","author":"JA Woyach","year":"2017","unstructured":"Woyach JA, Ruppert AS, Guinn D, Lehman A, Blachly JS, Lozanski A, Heerema NA, Zhao W, Coleman J, Jones D et al (2017) BTK(C481S)-mediated resistance to ibrutinib in chronic lymphocytic leukemia. J Clin Oncol 35:1437\u20131443","journal-title":"J Clin Oncol"},{"key":"554_CR73","first-page":"1770.e14","volume":"173","author":"YM Wu","year":"2018","unstructured":"Wu YM, Cieslik M, Lonigro RJ, Vats P, Reimers MA, Cao X, Ning Y, Wang L, Kunju LP, de Sarkar N et al (2018) Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer. Cell 173:1770.e14\u20131782.e14","journal-title":"Cell"},{"key":"554_CR74","doi-asserted-by":"crossref","DOI":"10.1080\/15384047.2023.2219470","volume":"24","author":"L Xiao","year":"2023","unstructured":"Xiao L, Liu Y, Chen H, Shen L (2023) Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments. Cancer Biol Ther 24:2219470","journal-title":"Cancer Biol Ther"},{"key":"554_CR75","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1039\/D3MD00004D","volume":"14","author":"Z Yan","year":"2023","unstructured":"Yan Z, Du Y, Zhang H, Zheng Y, Lv H, Dong N, He F (2023) Research progress of anticancer drugs targeting CDK12. RSC Med Chem 14:1629\u20131644","journal-title":"RSC Med Chem"},{"key":"554_CR76","doi-asserted-by":"publisher","unstructured":"Yap TA, Elhaddad AM, Grisham RN, Hamm JH, Marks DK, Shapiro G, Le Corre C, Li J, Lin TT, Liu F et al (2023) First-in-human phase 1\/2a study of a potent and novel CDK2-selective inhibitor PF-07104091 in patients (pts) with advanced solid tumors, enriched for CDK4\/6 inhibitor resistant HR+\/HER2- breast cancer. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.3010","DOI":"10.1200\/JCO.2023.41.16_suppl.3010"},{"key":"554_CR77","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/nchembio.2166","volume":"12","author":"T Zhang","year":"2016","unstructured":"Zhang T, Kwiatkowski N, Olson CM, Dixon-Clarke SE, Abraham BJ, Greifenberg AK, Ficarro SB, Elkins JM, Liang Y, Hannett NM et al (2016) Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors. Nat Chem Biol 12:876\u2013884","journal-title":"Nat Chem Biol"}],"updated-by":[{"DOI":"10.1038\/s44318-026-00862-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000}}],"container-title":["The EMBO Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44318-025-00554-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1038\/s44318-025-00554-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44318-025-00554-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T09:51:54Z","timestamp":1786960314000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1038\/s44318-025-00554-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,8]]},"references-count":78,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2025,10,15]]}},"alternative-id":["554"],"URL":"https:\/\/doi.org\/10.1038\/s44318-025-00554-6","relation":{},"ISSN":["0261-4189","1460-2075"],"issn-type":[{"value":"0261-4189","type":"print"},{"value":"1460-2075","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,8]]},"assertion":[{"value":"17 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SA and RCC are named inventors on patents concerning CDK7 inhibitors, which have been licensed to Carrick Therapeutics, own shares in and has received royalties from Carrick Therapeutics. RCC is on the advisory board for Carrick Therapeutics. SA, LB and CLB have also received research funding from Carrick Therapeutics. EO was funded by a PhD programme with funding from Carrick Therapeutics.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure and competing interests statement"}}],"article-number":"12"}}